GLP-1 weight loss claims on TikTok: what the data actually says

What's this video probably claiming?

Accounts like @glp_1_weightloss_canada tend to fall into a predictable pattern: personal transformation narratives, dose progression tips, and confident claims about how much weight you can expect to lose on semaglutide or tirzepatide. Given the Canadian context, there's likely some discussion of access, cost, and possibly compounded versions of these medications. Common claims in this category include rapid weight loss timelines, appetite suppression as a near-universal experience, and the suggestion that GLP-1 medications are appropriate for anyone who wants to lose weight. Some creators in this space also conflate different GLP-1 agents as if they perform identically, which they don't. Without a transcript, we're working from patterns, but the patterns in this niche are consistent enough to analyze meaningfully.

What does the science actually show?

The clinical trial data on GLP-1 receptor agonists is genuinely impressive, but it comes with context that most TikTok videos skip entirely. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that semaglutide 2.4mg weekly produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity but without diabetes. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at its highest dose produced an average 22.5% body weight reduction over 72 weeks. These are population averages. Roughly 10-15% of participants in these trials were classified as non-responders, losing less than 5% of body weight. Side effect profiles matter too: nausea affected around 44% of semaglutide users in STEP 1, and gastrointestinal events caused discontinuation in a meaningful minority of participants. These are not minor footnotes.

Where does the social media noise diverge from clinical reality?

Several divergences from clinical reality appear repeatedly in GLP-1 content. First, creators often present their own results as typical. If someone lost 30 pounds in three months, that is an outlier outcome, not a baseline expectation. Second, there is routine conflation of different agents: semaglutide, tirzepatide, liraglutide, and retatrutide have different mechanisms, efficacy profiles, and side effect rates. Liraglutide (Saxenda), for instance, produces roughly 5-8% average weight loss versus semaglutide's 15%, a difference that matters enormously for patient expectations. Third, Canadian creators sometimes discuss compounded semaglutide without adequately flagging that compounded products are not Health Canada-approved and have not been tested for bioequivalence with brand-name Ozempic or Wegovy. That is a regulatory and safety distinction, not a technicality. Fourth, the weight regain data after stopping these medications is almost never discussed: Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within one year of stopping semaglutide.

What should you actually know?

GLP-1 receptor agonists are among the most effective pharmacological tools for weight management currently available, and the clinical evidence supporting them is real. But the TikTok version of this story is consistently edited for optimism. What gets cut: the fact that insurance coverage in Canada remains inconsistent and out-of-pocket costs for Wegovy can exceed $400 CAD per month; that these medications are indicated for specific BMI thresholds or weight-related comorbidities, not cosmetic weight loss; that long-term cardiovascular data, while promising from the SELECT trial (Lincoff et al., 2023, NEJM) for semaglutide, is still accumulating for newer agents like tirzepatide and retatrutide; and that the decision to start any GLP-1 medication should involve a licensed prescriber reviewing your full medical history, not a TikTok comment section. If you are considering these medications, a regulated telehealth platform with actual clinicians reviewing your case is a meaningfully different category of care than crowdsourced dosing advice.